Fair value · Korsana Biosciences, Inc. (KRSA) · updated 2026-11-18 · from 10-K FY2025
Korsana Biosciences trades at $33.26. That price implies a P/E of 1.0×.
Cboe · delayed 15 min · as of 15:38 ET
Are those assumptions reasonable? Use KRSA’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- P/E
- 1.0×
price ÷ trailing EPS
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 15:38 ET.
Inputs come from the FY2025 10-K filed (accession 0001193125-26-132193); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
Korsana Biosciences, Inc.- Revenue
- $2.1M
- Diluted EPS
- $-1.11
- Free cash flow
- $-3.3M
- operating cash flow − capital expenditure
- Diluted shares
- 3.2M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-30 · accession 0001193125-26-132193
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q3 FY2026 (filed 2026-11-05).
Open this filing on sec.govNeed KRSA data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.